Posted by Michael Wonder on 22 Jan 2021
Yescarta approved in Japan for treatment of patients with relapsed/refractory large B-cell lymphomas
22 January 2021 - Approval based on phase 2 study conducted in Japan and previous pivotal trial data.
Daiichi Sankyo today announced the Japan Ministry of Health, Labour and Welfare has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor T-cell therapy, for the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.
The approval of Yescarta in Japan is based on data from the global pivotal trial conducted by Kite (ZUMA-1) and results of a Phase 2 study conducted by Daiichi Sankyo in Japan.
